Related Experiment Videos
Effect of D-penicillamine on human granulopoiesis in vitro
Abstract:
The effect of D-penicillamine on human bone marrow granulocyte-monocyte precursor cells (CFU-C) is studied in vitro. Bone marrow samples were obtained from 47 donors (40 patients and 7 healthy volunteers) and cultured in semisolid agar in the presence of various concentrations of the drug. We found an inhibitory, possibly dose-dependent, effect of D-penicillamine on colony formation. The pathophysiological mechanism and the clinical relevance of this effect remain poorly understood. These findings, however, emphasize the need for careful monitoring of the granulocyte counts during D-penicillamine therapy.
Insights
D-penicillamine may inhibit human bone marrow colony formation in vitro. Careful monitoring of granulocyte counts is recommended during D-penicillamine therapy due to potential effects on precursor cells.
Area of Science:
- Hematology
- Pharmacology
- Cell Biology
Background:
- D-penicillamine is a chelating agent used to treat various conditions, including rheumatoid arthritis and Wilson's disease.
- Its effects on hematopoietic precursor cells are not fully understood.
- Human bone marrow granulocyte-monocyte precursor cells (CFU-C) are crucial for innate immunity.
Purpose of the Study:
- To investigate the in vitro effects of D-penicillamine on human bone marrow CFU-C.
- To determine if D-penicillamine exhibits a dose-dependent inhibitory effect on CFU-C colony formation.
Main Methods:
- Human bone marrow samples were obtained from 47 donors.
- Cells were cultured in semisolid agar with varying concentrations of D-penicillamine.
- Colony formation was assessed to evaluate drug effects.
Main Results:
- D-penicillamine demonstrated an inhibitory effect on CFU-C colony formation in vitro.
- The inhibition appeared to be dose-dependent.
- The precise pathophysiological mechanism requires further investigation.
Conclusions:
- D-penicillamine may negatively impact human bone marrow precursor cell function.
- Clinical monitoring of granulocyte counts is essential during D-penicillamine treatment.
- Further research is needed to elucidate the clinical significance of these findings.